General Updates

Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 20 June 2026 National Stock Exchange of India Limited BSE Limited Scrip Symbol: SUNPHARMA Scrip Code: 524715 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition This is to inform that Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or affiliates referred to as “Sun Pharma” or “Company”), has entered into an agreement pursuant to which Sun Pharma has agreed to acquire 100% outstanding shares of Innovcare Lifesciences Private Limited, a company based in Mumbai and engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. Annexure A, enclosed herewith, provides the particulars of the disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Part A of Schedule III. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives. Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Annexure A Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Sl. Particulars Information a) Name of the target entity, details in brief Innovcare Lifesciences Private Limited such as size, turnover etc. (“Innovcare”), a company duly incorporated under Companies Act, 2013, and having its registered office at Mumbai, Maharashtra, India, is engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The revenue from operations for FY 2025-26 was INR 94.06 crores. b) Whether the acquisition would fall within No, the transaction in not a related party related party transaction(s) and whether transaction and promoter / promoter group does the promoter/ promoter group/ group not have any interest in the entity whose securities companies have any interest in the entity are being acquired. being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” c) Industry to which the entity being acquired Pharmaceuticals and Healthcare belongs d) Objects and effects of acquisition Strategic investment to strengthen product (including but not limited to, disclosure of portfolio of the Company reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) e) Brief details of any governmental or None regulatory approvals required for the acquisition f) Indicative time period for completion of On or before 31 July 2026 the acquisition g) Nature of consideration - whether cash Cash Consideration consideration or share swap and details of the same h) Cost of acquisition or the price at which Cash consideration aggregating ~Rs 271.2 Crores. the shares are acquired Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives. Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 i) Percentage of shareholding/ control Agreement to acquire 100% outstanding shares. acquired and/ or number of shares acquired j) Brief background about the entity acquired Innovcare is engaged in the business of marketing, in terms of products/line of business distribution and sale of pharmaceutical drugs, acquired, date of incorporation, history of nutraceutical and cosmeceutical products. last 3 years turnover, country in which the acquired entity has presence and any other Innovcare was incorporated on 21 July 2014. significant information (in brief) The revenue from operations for previous three years is as follows, FY Turnover (in INR Crores) 2025-26 94.06 2024-25 86.09 2023-24 80.93 Countries in which Innovcare has presence: India Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives.